Treatment with plasmapheresis, immunoglobulins and rituximab for chronic-active antibody-mediated rejection in kidney transplantation: Clinical, immunological and pathological results

Table 7 Analysis of kidney functional tests, proteinuria, MFI and DSAs-C1q fixing ability at diagnosis in functioning and non-functioning grafts at 24 mo

	PE-IVIG-RTX group(n = 9)		P-value	Control group(n = 12)		P-value
	Functioninggraft(n = 6)	Non-functioning graft(n = 3)		Functioninggraft(n = 8)	Non-functioninggraft(n = 4)
Creatinine, mg/dL	1.75 (1.2-2.7)	2 (1.9-3)	0.167	1.4 (0.9-2.3)	2.9 (2.4-3.7)	0.04
GFR, mL/min	47.9 (31-65.4)	55.4 (23.9-63.8)	0.905	52 (34.5-88.1)	30.5 (18.9-33.6)	0.04
Proteinuria, g/d	1.55 (1.3-2.5)	1.8 (1-4)	0.905	1.7 (0.8-7.3)	1.1 (0.3-2.6)	0.154
Donor age, yr	61 (37-63)	44 (43-80)	0.796	50.5 (18-82)	48 (25-55)	0.799
MFI	11600 (2700-24400)	7400 (7000-10300)	0.714	4500 (900-19300)	13200 (1700-24700)	0.533
C1q-fixing DSA, n (%)	3/6 (50)	1/3 (33.3)	0.595	2/7(28.6)	2/3(66.7)	0.333

DSA: Donor-specific antibodies.